<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03757065</url>
  </required_header>
  <id_info>
    <org_study_id>ALPN000-001</org_study_id>
    <nct_id>NCT03757065</nct_id>
  </id_info>
  <brief_title>Cell Surface Marker Expression in Autoimmune Diseases</brief_title>
  <acronym>CASCADE</acronym>
  <official_title>A Cross-Sectional Study of Cell Surface Marker Expression in Participants With Autoimmune or Inflammatory Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alpine Immune Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alpine Immune Sciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to explore the expression of cell-surface markers in the following
      seven disease areas: (a) systemic lupus erythematosus, (b) Sjogren's syndrome, (c) multiple
      sclerosis, (d) systemic sclerosis, (e) Crohn's disease, (f) ulcerative colitis and (g)
      inflammatory myositis.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">June 12, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>CD28 Expression</measure>
    <time_frame>At enrollment</time_frame>
    <description>Percentage of CD28+ T cells in peripheral blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ICOS Expression</measure>
    <time_frame>At enrollment</time_frame>
    <description>Percentage of ICOS+ T cells in peripheral blood</description>
  </primary_outcome>
  <number_of_groups>7</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <condition>Sjogren's Syndrome</condition>
  <condition>Multiple Sclerosis</condition>
  <condition>Systemic Sclerosis</condition>
  <condition>Crohn's Disease</condition>
  <condition>Ulcerative Colitis</condition>
  <condition>Inflammatory Myositis</condition>
  <arm_group>
    <arm_group_label>Systemic Lupus Erythematosus</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Sjogren's Syndrome</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Sclerosis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Systemic Sclerosis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Crohn's Disease</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Ulcerative Colitis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Inflammatory Myositis</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adults with systemic lupus erythematosus, Sjogren's syndrome, systemic sclerosis, multiple
        sclerosis, Crohn's disease, ulcerative colitis, or inflammatory myositis.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female participants 19 years of age or older.

          2. Participant or legal surrogate able and willing to provide written, informed consent.

          3. Participant is, or has been undergoing care for one of the specified diseases in a
             participating centre with a confirmed clinical diagnosis of the specified disease.

          4. Participant has or will provide the relevant peripheral blood (required) and normal
             practice tissue specimens (if available).

          5. Participant has one of the following target auto-immune or inflammatory diseases
             diagnosed according to local clinical practice guidelines:

               1. Crohn's Disease

               2. Inflammatory myositis

               3. Multiple sclerosis

               4. Sjogren's syndrome

               5. Systemic lupus erythematosus

               6. Systemic sclerosis

               7. Ulcerative colitis

        Exclusion Criteria:

          1. Participants receiving investigational therapy within 30 days or 5 half-lives,
             whichever is longer, prior to enrolment.

          2. Participants suffering from any additional disease that may interfere with the
             biomarker signals as per the investigator's discretion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Hillson, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alpine Immune Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GI Research Institute</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2K5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Pack Arthritis Center</name>
      <address>
        <city>Vancouver</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>November 27, 2018</study_first_submitted>
  <study_first_submitted_qc>November 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 28, 2018</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Myositis</mesh_term>
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

